Back to news overview

What makes the Flemish biotech so successful?

The recent news about the takeover bids on VUB spin-off Ablynx and start-up Aelin Therapeutics who raised €27 million capital, makes us wonder why international investors ace on Flemish start-ups? Els Beirnaert (CEO Aelin Therapeutics) and Johan Cardoen (Managing Director VIB) talk about their experiences and share their vision in Knack.